We are thrilled to announce a major milestone for our company, Aureka Biotechnologies, Inc.! We have successfully secured a multimillion-dollar seed funding round, marking a significant achievement in our journey. This round of funding was led by esteemed investors, K2 Venture Partners 险峰旗云 and 纽尔利资本 NRL Capital, further validating the pioneering work we are doing.
The substantial investment will be dedicated to advancing our state-of-the-art AI+ high-throughput digital biotechnology platform, empowering us to drive innovation and revolutionize the development of large-molecule drugs. Our cutting-edge platform will pave the way for transformative breakthroughs in the pharmaceutical industry.
We extend our deepest gratitude to our exceptional team and visionary investors for their unwavering support. Together, we are poised to reshape the future of medicine through groundbreaking digital biological solutions.
• MIT Technology Review
https://www.mittrchina.com/news/detail/12093
• VBDATA
